qoosa.com

© CarbonNYC

DUSA Pharmaceuticals (DUSA) is a small-cap biotechnology company that has recently turned profitable, presenting an investment with fantastic return opportunities. It boasts rapidly increasing sales and a gross margin that exceeds 80%. The company is an integrated dermatological biotechnology company whose main products treat the common skin condition actinic keratoses (AK), which are precancerous lesions caused by sun exposure.

AKs areresponsible for over 8 million visits to dermatologists annually, and that number is growing quickly. DUSA has what appears to be a superior treatment option in this fast growing market, with the only side effects being slight sensitivity. 2010 was the first profitable year in the company's history, and sales have continued to increase at a compound annual growth rate of nearly 30%. They currently have only 5% of market share, so there is significant room for growth in the stock.

© Plutor

By the year 2020 nearly 20% of the American population will be over the age of 65. This percentage will grow higher and higher as record numbers of people start retiring and life expectancy rises. Such a staggering number of individuals who will undoubtedly be needing constant or near-constant medical attention and assistance spell serious trouble for the medical industry, which is unprepared.

In Japan where the elderly population is nearing a quarter of the country's total population, considerable investment has been put into robotics industries, the hope being that they will ultimately be able to turn over the care of their seniors to robots capable of taking blood pressure, performing injections, and so on. American industries aren't far behind in this foresight. Are medical assistant schools, clinical technician schools, and health administration schools really on their way to becoming obsolete institutions in our healthcare world, soon to be replaced by factories pumping out whirling machines holding syringes and bedpans straight out of The Twilight Zone?

I don't think so. While it is certainly true that sheer data alone dictates the someday necessity of artificially created assistants in the medical world, there will undoubtedly be a realization at some point that there is validity to the belief that human touch can heal. Physicians of the future will see the difference between the way their patients respond to a robot swabbing their arm and when a human performs the task. Again I'll reiterate that we simply won't have the peoplepower to cover all necessary tasks that will come with the care of such a huge elderly population. But for those times when physicians, specialists, and surgeons can tell that for the sake of the psychological well being of their patients they must have humans assisting them, the role of the healthcare professional will be in demand.

Technology companies flaunting these new creations like to say no hospital of the future will employ a living healthcare assistant when a robot can do the job, but that's actually pretty shortsighted. The long-term outlook seems to indicate that, while fiscally sound, such confidence in artificial autonomy helping with healthcare forgets that while robots may be the caretakers, they'll never be who's taken care of. Those who are taken care of are who will decide who performs the task, and they will likely demand human involvement for years to come.

© familymwr

In the field of birth medicine, it seems that America is falling behind. Many health care officials believe that it's due to some of our practices and not finding a better way to incorporate updated information into the healthcare process. By using updated, state-of-the-art equipment, like informatics, it's the hope that this startling figure can be lowered.
According to an article by CNN, the US is ranked number two in the world of industrialized nations as having the highest infant mortality rate. Some officials argue this figure but regardless if we're number two or three, we're still very high on the list. There have been a lot of advancements and preventative measures taken lately that have designed to increase the care of our country's newborns.
There's a new hormone gel that's been used in hospitals that said to reduce the premature birth rate by nearly half among women who are believed to be a high risk. The outcome of studying this gel's efficacy has shown that, with this hormone treatment, medical professionals believe that its use could save as many as ten thousand lives every year. This advancement has many in the childcare industry very excited about the possibilities. This is due to the fact that, in America, premature birth is the number one cause of death and illness among babies. But this problem isn't just a sign of hope for America alone.
Some studies have shown that nearly thirteen million babies worldwide, around a half a million of that figure here in America are born prematurely every year. This number has seen a steady rise that's kept up with population. It's the hope that treatments, as well as other advancements, will help reduce this number to a trickle and improve the overall quality of life for newborns the world over.
Only about a third of births are due to decisions made by the doctor, which is usually for health reasons. The rest are spontaneous labor births. The hormone treatment, which is a progesterone gel, is inserted vaginally in women who run a high risk. Doctors usually constitute this risk in women who have a short cervix which are known to soften too early in the pregnancy and result in a premature labor.
It's the belief that as many as 2% of the nation's half a million preterm births could be prevented through the use of this hormone treatment. As many as ten thousand babies a year could be saved from a premature delivery. It's estimated that decreasing this number by these figures alone could save America's Healthcare system around twelve million a year. It's the hope that the use of this treatment and other advancements will continue to increase our knowledge of the human body and lower occurrence of this epidemic issue.